B Bristol-Myers Squibb
| Market Cap | $121.69B |
| P/E Ratio | 17.23 |
| Forward P/E | 9.71 |
| Dividend Yield | 4.23% |
| Beta | 0.27 |
| 52W Range | $41.67 - $61.73 |
| # Hedge Funds | 10 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Hedge Fund Ownership
| Investor 11 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Richard Pzena Pzena Investment Management | 2.90% | $967.87M | 17,943,503 | Add 20.41% |
| Bill Miller Miller Value Partners | 2.05% | $5.83M | 108,000 | — |
| Kahn Brothers Group Kahn Brothers Group | 1.93% | $10.91M | 202,196 | Reduce 25.75% |
| Hillman Value Fund Hillman Capital Management | 1.83% | $2.91M | 53,966 | Reduce 22.28% |
| Charles Bobrinskoy Ariel Investments | 0.43% | $39.52M | 732,677 | Buy |
| Dodge & Cox Dodge & Cox | 0.21% | $381.80M | 7,078,250 | Reduce 4.65% |
| Tweedy Browne Co. Tweedy Browne Co LLC | 0.07% | $908.00K | 16,842 | Add 16.42% |
| FPA Queens Road Small Cap Value Fund Bragg Financial Advisors | 0.05% | $1.63M | 30,157 | Reduce 7.37% |
| David Katz Matrix Asset Advisors | 0.02% | $211.00K | 3,929 | Buy |
| Mairs & Power Growth Fund Mairs & Power Inc | 0.01% | $1.34M | 24,938 | Reduce 5.51% |
| Jensen Investment Management Jensen Investment Management | 0.00% | $0 | 0 | Sold |
Insider Trading
| Insider Name of the company insider who made the trade 2 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Elkins David VEVP, Chief Financial Officer | Sale | 4,481 | $62.05 | $278.05K | 01 Apr 2026 | 01 Apr 2026 |
| Elkins David VEVP, Chief Financial Officer | Sale | 25,519 | $61.60 | $1.57M | 01 Apr 2026 | 01 Apr 2026 |
Frequently Asked Questions
What is BMY stock price today?
Bristol-Myers Squibb (BMY) is currently trading at $59.60. The stock has a 52-week range of $41.67 to $61.73 and a market capitalization of $121.69B.
Is BMY a good stock to buy in 2026?
Bristol-Myers Squibb has a P/E ratio of 17.2 (forward P/E: 9.7), a dividend yield of 4.23%, and 1-year performance of +9.4%. 11 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling BMY stock?
There have been 2 insider transactions for BMY in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has BMY stock performed over the past year?
Bristol-Myers Squibb (BMY) has returned +9.4% over the past 12 months. The stock traded between $41.67 and $61.73 during this period, and is currently at $59.60.
Which hedge funds own BMY (Bristol-Myers Squibb)?
11 tracked hedge funds currently hold BMY in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is BMY's market cap and valuation?
Bristol-Myers Squibb (BMY) has a market capitalization of $121.69B. The trailing P/E ratio is 17.2 and forward P/E is 9.7. The stock is classified in the Healthcare sector.
What is BMY's revenue and profitability?
Bristol-Myers Squibb reported revenue of $48.19B with net income of $7.05B and a profit margin of 0.15%. The stock has a beta of 0.27.
What sector is BMY in and who are its biggest institutional holders?
Bristol-Myers Squibb (BMY) operates in the Healthcare sector. It is held by 11 tracked hedge funds. See the ownership table above for the complete list.